What is DSIP and what research has been done on it?

Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit cerebral venous blood by Monnier et al. in 1977. It is naturally present in the human hypothalamus, pituitary, and peripheral tissues including the intestine and pancreas, where it participates in neuroendocrine signaling. Research on DSIP spans sleep-architecture modulation — including documented delta-wave sleep induction in animal models — neuroendocrine regulation (ACTH suppression in hypothalamic preparations), stress response modulation via opioid system interaction, and antioxidant properties in rodent brain models. Graf et al. (1984) conducted human sleep studies with small cohorts reporting subjective sleep quality improvements following DSIP infusion. No completed Phase II or Phase III randomized controlled trials of DSIP exist.

Why does DSIP's endogenous nature matter for its PCAC review?

DSIP's status as an endogenous human peptide — naturally present in the hypothalamus, pituitary, and peripheral tissues — is a substantively relevant factor in the PCAC evaluation. Endogenous compounds carry an inherently favorable safety context because human physiology has evolved with the molecule present: the metabolic clearance pathways, receptor interactions, and physiological effects of the compound at endogenous concentrations are part of normal human biology. This informs a lower presumed risk profile compared to entirely synthetic novel compounds. In preclinical research, no significant toxicological signals have been reported across the dose ranges studied. The PCAC still applies the full four-factor analysis, but endogenous status strengthens the safety component of Factor 2 and is a meaningful consideration in the committee's overall assessment of whether compounding is appropriate.

What is the FDA PCAC review date for DSIP and what happens after the hearing?

DSIP is scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026 — the second day of a two-day PCAC session covering multiple peptide compounds including KPV, Semax, Epitalon, and others. Following the hearing, the committee issues a recommendation to FDA, but this recommendation does not constitute a final regulatory action. FDA then opens a public comment period during which researchers, clinicians, compounding pharmacies, and patient advocates may submit additional evidence or clinical need documentation. A formal agency determination — which will either place DSIP on the positive 503A list, maintain Category 2 status, or finalize restriction — typically follows six months to over one year after the advisory committee meeting, depending on comment volume and regulatory complexity.

DSIP FDA PCAC July 2026: 503A Review and Research Access

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 24, 2026 to evaluate the 503A bulk drug substance status of Delta Sleep-Inducing Peptide (DSIP). For researchers and clinicians who have sourced DSIP through Section 503A compounding pharmacies, the committee's determination will directly affect domestic research access to this nonapeptide. This article traces DSIP's research history, explains its regulatory position in the 503A framework, and outlines the factors that will determine the July 24 outcome.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and regulatory documentation. It does not constitute medical or legal advice. See the DSIP compound library profile for full compound data, and the PCAC overview article for context on all compounds under review at the July 2026 meeting.

What DSIP is and why it is compounded

Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide — a nine-amino-acid sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) — originally isolated from rabbit cerebral venous blood by Monnier and colleagues in 1977. Unlike many research peptides that are entirely synthetic, DSIP is endogenous: it is naturally present in the hypothalamus, pituitary gland, and peripheral tissues including the intestine and pancreas, where it participates in neuroendocrine and sleep-regulatory circuits.

The compound was named for its ability to induce delta-wave (slow-wave) sleep activity when infused into the rabbit thalamus in the original isolation experiments. Subsequent research has substantially broadened the investigation of DSIP's biological profile beyond sleep to include stress response modulation, neuroendocrine regulation, antioxidant activity, and anti-cancer properties in preclinical models.

Because no FDA-approved pharmaceutical preparation of DSIP exists, its clinical and investigational use in the United States has occurred through 503A compounding pharmacies. The July 24, 2026 PCAC review is the regulatory event that will determine whether that channel continues.

The 503A framework and DSIP's current classification

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies preparing individualized patient-specific prescriptions. Bulk drug substances used in 503A preparations must appear on an FDA-maintained positive list, be components of FDA-approved drugs, or meet specified alternative criteria. The PCAC advises FDA on which compounds should be placed on, maintained on, or removed from that positive list.

DSIP is currently under 503A Category 2 review — indicating that the FDA has identified questions warranting advisory committee evaluation, as it has for BPC-157, TB-500, KPV, and Semax in the same review cycle. Category 2 status represents scrutiny rather than prohibition, with the July 24 meeting providing the formal evaluation opportunity.

The research evidence base

Sleep and neuroendocrine research: The most replicated body of DSIP preclinical research concerns its effects on sleep architecture and neuroendocrine function. Schoenenberger et al. (1983, European Journal of Pharmacology) documented DSIP-induced increases in delta sleep time in cat models using electroencephalographic measurement. Iyer and Bhargava (1983, Pharmacology, Biochemistry and Behavior) extended these findings to rodent sleep models. In neuroendocrine contexts, DSIP has been shown to modulate corticotropin (ACTH) secretion and participate in the hypothalamic-pituitary-adrenal axis, with Nakagawa et al. (1985) reporting DSIP-mediated suppression of ACTH release in rat hypothalamic preparations.

Stress response and antioxidant research: Research from Ashmarin's group and associated Russian laboratories has documented DSIP activity in stress-related paradigms. Yarygin et al. (1990) reported that DSIP administration reduced stress-induced physiological markers in rat models of repeated immobilization stress. Sudakov et al. (2003, Peptides) reviewed the compound's interactions with opioid systems, noting modulation of pain and stress responses in rodent models that may reflect DSIP's activity in endogenous stress regulatory circuits. Mendzheritsky et al. (2003) documented antioxidant properties of DSIP in rat brain models subjected to oxidative challenge.

Anti-tumor research: A distinct body of literature — primarily from Soviet and Russian research groups — has investigated DSIP in oncological contexts. Khavinson et al. have documented peptide bioregulator effects including DSIP-analogues in aging and anti-tumor models, though this research tradition has been less extensively replicated by independent Western laboratories.

Pharmacokinetics: DSIP is an endogenous peptide and as such is subject to rapid clearance. Published half-life estimates in plasma range from minutes to low hours depending on measurement method, enzyme inhibitor use, and species. The research literature has used subcutaneous, intraperitoneal, intravenous, and intranasal routes in animal models, with the pharmacokinetic profile varying substantially by route.

Human data: DSIP has been examined in human sleep studies, including early work by Graf et al. (1984, European Archives of Psychiatry and Neurological Sciences) reporting subjective improvements in sleep quality in small cohorts of patients with chronic insomnia following DSIP infusion. These studies involve small sample sizes and do not meet modern randomized controlled trial standards. No completed Phase II or Phase III RCTs of DSIP have been published. Human evidence remains limited to small exploratory cohorts.

The endogenous compound argument

DSIP holds a regulatory argument distinct from many other PCAC-reviewed peptides: it is an endogenous compound naturally produced by the human body. This status — shared with compounds like oxytocin and VIP — informs several aspects of the PCAC analysis:

The safety threshold for endogenous peptides is generally approached differently by regulatory bodies than for purely synthetic compounds, given the biological familiarity with the molecular target and the long evolutionary history of the peptide's presence in human physiology. The preclinical safety record for DSIP administration is consistent with this expectation: no significant toxicological signals have been reported in the published literature at doses studied in rodent models.

However, endogenous status does not automatically support positive 503A listing — the committee still applies the four-factor analysis and requires clinical evidence sufficient to establish plausibility for compounded use.

The no-approved-equivalent argument

As with all compounds under review in the July 2026 PCAC cycle, the central regulatory question includes whether an FDA-approved commercial equivalent exists for the clinical uses for which DSIP is compounded. The analysis for DSIP is definitive: no FDA-approved drug contains DSIP as an active ingredient. No NDA or ANDA referencing DSIP exists.

The approved pharmacological options for sleep disorders — benzodiazepines, non-benzodiazepine GABA modulators, melatonin receptor agonists, orexin antagonists — represent alternatives addressing sleep indications through mechanisms entirely distinct from DSIP's endogenous neuropeptide pathway. Whether the committee views these alternatives as "suitable commercial alternatives" that reduce clinical need for compounded DSIP, or whether DSIP's endogenous mechanism and neuroendocrine profile constitute a sufficiently distinct therapeutic context, is a question the July 24 evaluation will address.

What the PCAC evaluates: four-factor analysis applied to DSIP

Factor 1 — Physical and chemical characteristics: DSIP is a nine-amino-acid nonapeptide with molecular weight of approximately 848 Da. Its small size and water solubility facilitate compounding in lyophilized powder formulations reconstituted for parenteral administration. The endogenous source of the compound and its characterization in published pharmacopoeial-quality synthesis protocols reduces some of the characterization uncertainty facing less well-studied peptides. Stability and sterility data from compounding operations will form part of the committee record.

Factor 2 — Safety and effectiveness evidence: The safety record is favorable across the published literature, consistent with its endogenous status. The effectiveness record is primarily preclinical, with the strongest data in sleep-architecture and neuroendocrine-modulation models. The human sleep data, while limited in methodological quality, provides at least a clinical signal. The committee will weigh whether this evidence profile meets the 503A plausibility standard.

Factor 3 — Historical use in compounding: DSIP has documented use through 503A compounders, primarily in contexts involving sleep disorders, stress-related conditions, and neuroendocrine support. Nominator submissions will present this usage data to the committee.

Factor 4 — Nature of the condition treated: The patient populations for whom DSIP has been compounded include individuals with chronic insomnia, sleep-maintenance disorders, and stress-related neuroendocrine dysregulation who have sought investigational options outside or in addition to approved therapeutics. The clinical context — addressing conditions with imperfect approved-drug options — bears on the committee's assessment of clinical need.

Outcome scenarios following July 24, 2026

Scenario A — Upgraded to Category 1 (positive listing). The committee finds the preclinical evidence base credible, compounding characteristics acceptable, and no adequate commercial substitute. 503A pharmacies may continue compounding DSIP without regulatory disruption.

Scenario B — Maintained at Category 2. Evidence is found insufficient for positive listing but not clearly adverse. Continued compounding availability in the near term, with regulatory uncertainty extending.

Scenario C — Restricted or prohibited from 503A compounding. If the committee recommends exclusion from the 503A Bulks List, and FDA finalizes that recommendation, 503A pharmacies could not use DSIP as a bulk drug substance. Given the absence of alternative regulated domestic sources, this would effectively end domestically supervised compounded DSIP access.

Regulatory timeline

Advisory committee recommendations do not constitute final regulatory action. Following the July 24 meeting, FDA typically opens a public comment period before proceeding to formal determination. The interval between an advisory committee meeting and a finalized agency determination has historically ranged from six months to over one year. Researchers and clinicians with stake in the outcome have standing to submit public comments during that window, presenting additional evidence or clinical need documentation directly to the FDA record.

Summary

DSIP's July 24, 2026 PCAC review will determine the regulatory future of its 503A availability. The compound's strongest arguments for positive listing are its endogenous human origin — which informs a favorable safety context — and the complete absence of any FDA-approved equivalent containing DSIP as an active ingredient. The preclinical evidence in sleep-architecture and neuroendocrine models is scientifically coherent, if limited in human validation. The primary uncertainty is whether the limited human clinical record meets the committee's evidentiary threshold, and whether approved sleep therapeutics are considered adequate substitutes by the committee.

For full compound chemistry, mechanism data, and preclinical literature citations, see the DSIP compound library profile. For the broader regulatory context of the July 2026 PCAC review, see the PCAC overview article.